Sentynl Selects myTomorrows to Lead Managed Access Program
Reinforcing its commitment to rare disease treatment access,Sentynl is transitioning its program to myTomorrows patient-centric platform. Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (“Zydus Group”), has appointedmyTomorrows, as the new global provider for its Managed Access Program (MAP). myTomorrows is a global health technology company that connects patients with […]